Nitric Oxide News and Research

RSS

New portable system can produce life-saving NO from air by means of electrical spark

Treatment with inhaled nitric oxide (NO) has proven to be life saving in newborns, children and adults with several dangerous conditions, but the availability of the treatment has been limited by the size, weight and complexity of equipment needed to administer the gas and the therapy's high price.

7 Jul 2015

New study identifies enzyme that causes obesity-related hypertension

Obesity is a serious health problem affecting approximately one-third of the adult population in the United States. Obese individuals have an increased risk of diabetes and cardiovascular disease, including hypertension. A recent study led by a University of Missouri researcher has identified the enzyme responsible for obesity-related hypertension -- a finding that could lead to new treatment options.

5 May 2015

Latest findings regarding nitric oxide offer new avenues to save lives

Professor Jonathan Stamler's latest findings regarding nitric oxide have the potential to reshape fundamentally the way we think about the respiratory system - and offer new avenues to save lives. It may be time to rewrite the textbooks.

13 Apr 2015

Northwestern University researchers find safer way to improve surgery outcomes

A Northwestern University research team potentially has found a safer way to keep blood vessels healthy during and after surgery.

7 Apr 2015

Researchers test effects of light therapy on brain function

Following up on promising results from pilot work, researchers at the VA Boston Healthcare System are testing the effects of light therapy on brain function in veterans with Gulf War Illness.

3 Apr 2015

Folic acid supplements can improve blood vessel dilation in older adults

Supplemental folic acid can enhance blood vessel dilation in older adults, according to Penn State researchers, suggesting that folic acid supplements may be an inexpensive alternative for helping older adults to increase skin blood flow during heat waves and reduce cardiovascular events.

1 Apr 2015

Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Working with lab animals and human heart cells, scientists from Johns Hopkins and other institutions have identified what they describe as "the long-sought culprit" in the mystery behind a cell-signaling breakdown that triggers heart failure. The condition, which affects nearly 6 million Americans and 23 million people worldwide, is marked by progressive weakening and stiffening of the heart muscle and the organ's gradual loss of blood-pumping ability.

19 Mar 2015

Inhaled Nitric Oxide still being used in preterm neonates despite evidence of short-term benefit

Inhaled Nitric Oxide (iNO) is a drug approved by the Food and Drug Administration that is commonly used in term and near-term neonates who have severe respiratory failure caused by pulmonary hypertension. Over the last decade there have been multiple large studies trying to determine a clinical use for iNO in preterm neonates, but despite evidence of short-term benefit, this drug has not been shown to improve long-term outcomes in preemies.

10 Mar 2015

Mallinckrodt enters into definitive agreement to acquire Ikaria

Mallinckrodt plc, a leading global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held critical care company, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion.

5 Mar 2015

Doctor's Best adds three new sports nutrition powders to its science-based supplement portfolio

Doctor's Best has introduced three new sports nutrition powders – Creatine, Branched Chain Amino Acids (BCAA) and L-Arginine - into its science-based supplement portfolio.

13 Feb 2015

AP39 compound could help lower heart rate, blood pressure, and blood vessel stiffness

A gas that gives rotten eggs their distinctive odour could one day form the basis of new cardiovascular therapies.

29 Jan 2015

Study examines effects of beetroot juice on physical function of COPD patients

A Wake Forest University study to investigate the effects of acute beetroot juice ingestion on the exercise capacity of COPD patients shows some promise, but a larger clinical trial is needed to verify results.

23 Jan 2015

Penn State researchers explore benefits of beet juice

Athletes who down beet juice before exercising to increase blood flow and improve performance may be surprised at the results of a recent study conducted at Penn State's Noll Laboratory. While beetroot juice rich in nitrates did not enhance muscle blood flow or vascular dilation during exercise, researchers found that it did "de-stiffen" blood vessels under resting conditions, potentially easing the workload of the heart.

20 Jan 2015

UH Case Medical Center researchers find that coenzyme A plays key role in cell metabolism

Case Western Reserve and University Hospitals Case Medical Center researchers and physicians have discovered that the molecule known as coenzyme A plays a key role in cell metabolism by regulating the actions of nitric oxide. Cell metabolism is the ongoing process of chemical transformations within the body's cells that sustains life, and alterations in metabolism are a common cause of human disease, including cancer and heart disease.

15 Jan 2015

One cup of blueberries per day could help reduce blood pressure, arterial stiffness

Just one cup of blueberries per day could be the key to reducing blood pressure and arterial stiffness, both of which are associated with cardiovascular disease.

8 Jan 2015

Deoxygenated hemoglobin triggers conversion of nitrite to nitric oxide

Understanding how nitrite can improve conditions such as hypertension, heart attack and stroke has been the object of worldwide research studies. New research from Wake Forest University has potentially moved the science one step closer to this goal.

14 Dec 2014

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.

9 Dec 2014